Disease relevance of Tumor Lysis Syndrome

• Brief report: tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia [1].
• Calcitriol in prolonged hypocalcemia due to the tumor lysis syndrome [2].
• Despite an overall survival rate of 43%, survival to discharge varied greatly (0 to 100%) among the 24 diagnostic groups: tumor lysis syndrome and systemic lupus erythematosus (3/3 patients each, 100%), hemolytic uremic syndrome (8/9 patients, 89%) [3].
• Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines [4].
• Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome [5].

High impact information on Tumor Lysis Syndrome

• Tumor lysis syndrome after tamoxifen flare [6].
• Difficult diagnostic and therapeutic cases: CASE 2. thymoma and tumor lysis syndrome in an adolescent [7].
• The vast majority of these patients had a malignancy and were in danger of developing tumor lysis syndrome (TLS) and subsequent acute uric acid nephropathy (AUAN) and were unable to take oral allopurinol [8].
• PURPOSE: To quantify the incidence and severity of tumor lysis syndrome (TLS) as a consequence of fludarabine therapy in patients with advanced chronic lymphocytic leukemia (CLL) [9].
• Pulse steroid therapy was associated with rapid improvement of renal function and kidney size, but a moderate degree of tumor lysis syndrome ensued [10].

Chemical compound and disease context of Tumor Lysis Syndrome

• When he received low-dose vincristine therapy daily with high-dose prednisone therapy given on alternate days, a fatal tumor lysis syndrome occurred [11].
• A 17-year-old boy had a tumor lysis syndrome after a single 200 mg/sq m dose of amsacrine [12].
• However, ARF may also develop due to aetiologies arising from cancer treatment or the disease itself, including: nephrotoxic chemotherapy agents, post-renal obstruction, compression and infiltration by malignancy, tumour lysis syndrome, uric acid, sepsis and contrast agent nephropathy [13].
• No significant rise in creatinine was seen and no cases of tumour lysis syndrome occurred [14].
• Acute tumor lysis syndrome has not been reported in marrow transplant patients receiving conventional preparative regimens as treatment for CML in blast crisis, and it is likely that its occurrence in this patient was precipitated by high-dose Ara-C [15].

Biological context of Tumor Lysis Syndrome

• With aggressive hydration, urine alkalinization, forced diuresis, and high-dose allopurinol, acute tumor lysis syndrome was not seen in three subsequent cases of CLL treated with ACE [16].

Anatomical context of Tumor Lysis Syndrome

• PURPOSE: To evaluate the frequency of metabolic complications and dialysis due to tumor lysis syndrome in patients with B-cell advanced-stage non-Hodgkin's lymphoma (NHL) and L3 leukemia at initiation of chemotherapy including the use of urate-oxidase [17].
• Dexamethazone-induced acute tumor lysis syndrome in a T-cell malignant lymphoma [18].
• Five oncologic emergencies (septic shock, syndrome of inappropriate antidiuretic hormone, tumor lysis syndrome, disseminated intravascular coagulopathy, and spinal cord compression) are defined and described physiologically and clinically [19].

Gene context of Tumor Lysis Syndrome

• Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification [20].
• CONCLUSIONS: As of September 26, 2005, screening for G6PD deficiency should be performed whenever possible prior to chemotherapy administration in patients at risk of developing tumor lysis syndrome [21].
• Furthermore, rational approaches to treat complications of tumor lysis syndrome by administration of the recombinant urate oxidase protein, also known as rasburicase, which corrects the biochemical defect present in humans, were discussed [22].
• Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma [23].
• The spontaneous occurrence of tumor lysis syndrome has not been previously reported; however, Cohen et al [24].

Analytical, diagnostic and therapeutic context of Tumor Lysis Syndrome

• The factors that had a statistically significant impact on survival were high creatinine (p = 0.00001) and blood urea nitrogen levels (p = 0.0001), the onset of tumor lysis syndrome (p = 0.01), and the need for dialysis (p = 0.009) [25].
• We present a case of tumor lysis syndrome in a patient with metastatic colon carcinoma that occurred 72 hrs after the initial course of a combination chemotherapy with irinotecan and 5-fluorouracil/leucoverin [26].
• Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine [27].

References